Ruxonib (ruxolitinib) cream 1.5%, 30 g

Product information

How it works

Ruxolitinib inhibits Janus kinases JAK1 and JAK2 involved in inflammatory signalling. Local application helps reduce skin inflammation and, in non-segmental vitiligo, may support repigmentation of treated areas.

Uses

How to use

• Apply a thin layer to affected areas twice daily.
• For vitiligo, do not treat more than 10% of body surface area at one time.
• For atopic dermatitis, do not treat more than 20% of body surface area at one time.
• For external use only; avoid the eyes, mouth and mucous membranes.
• Wash hands after application unless the hands are being treated.

Important: Duration of use depends on the skin condition. Follow the official leaflet supplied with the specific pack.

Precautions

• Do not use in case of hypersensitivity to any component.
• Do not use during pregnancy or breastfeeding.
• Use caution with an active skin infection; stop application if a serious reaction occurs.
• Safety in children under 12 years has not been established.

Possible adverse reactions

Application-site acne, redness, itching or irritation, headache and nasopharyngitis symptoms may occur. Refer to the official leaflet for the complete list.

Storage

Store below 30 °C in a dry place protected from light. Do not freeze. Keep out of reach of children.